IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

NCT06849986 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Soft Tissue Sarcomas
Angiosarcoma
Fibrosarcoma
Leiomyosarcoma
Pleomorphic Liposarcoma
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Desmoplastic Small Round Cell Tumor

Interventions

DRUG: Tislelizumab+liposomal doxorubicin+ifosfamide

Sponsor

Fudan University